Will Anything Stop Pfizer's Inversion Plans?

The video discusses tax inversions in the pharmaceutical industry, focusing on Pfizer's strategies. It covers Pfizer's past attempts with AstraZeneca, their interest in Actavis, and the financial implications of such deals. The video highlights the importance of friendly acquisitions and the need for Pfizer to replace lost blockbuster revenues.

What are the potential advantages of tax inversions for pharmaceutical companies?

How did Pfizer's approach to acquisitions change after their experience with AstraZeneca?

What factors might influence Pfizer's decision to pursue a deal with Actavis?

What challenges does Pfizer face in replacing lost blockbuster revenues?

Discuss the implications of AstraZeneca's rejection of Pfizer's offer.